News

STAT18h
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
India Today on MSN38m
Tirzepatide outperforms semaglutide in clinical trial with faster weight loss
A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...
Fierce Biotech21h
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Novo Nordisk Strikes $2.2 Billion Deal With Septerna to Develop New Obesity Treatments
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Weight-Loss Drugs Aren’t Really About Weight
The best metric is not weight, but a particularly toxic kind of fat.
The Press Democrat1h
Medi-Cal coverage of weight loss drugs on chopping block under governor’s proposal
Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...
Which Weight-Loss Drug Works the Best?
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Why Weight-Loss Developer Stocks Tumbled on Tuesday
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
Novo Nordisk partners with US biotech to boost pipeline of new obesity drugs
Novo Nordisk has agreed a partnership worth up to $2.2bn with US biotech Septerna, as the Danish drugmaker tries to shore up its pipeline of potential next-generation obesity drugs. The pharmaceutical ...